Brief update on the LEADER cardiovascular outcomes trial

10' education - Oct. 15, 2017 - Prof. Neil Poulter, cardiologist, London, UK

Video navigation menu

Aim and design of the LEADER trial 00:34
Primary and key secondary cardiovascular outcomes 02:15
What about patients with versus those without prior ischemic event? 04:01
Occurrence of severe hypoglycaemia over time 05:19
Summary of results 06:48

Educational information

Persons with type 2 diabetes are at an elevated risk for cardiovascular disease. Results of several recent cardiovascular outcomes trials indicate that selected GLP-1 agonists have significant cardiovascular benefits. This recording aims to highlight the practical implications of the LEADER study data with the GLP-1 agonist liraglutide.

Faculty

Prof. Neil Poulter, FMedSci, cardiologist, Faculty of Medicine, National Heart & Lung Institute; Professor of Preventive Cardiovascular Medicine, Imperial College London, United Kingdom

Member of the Executive Board and President Elect of the International Society of Hypertension

Disclosures

This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme. PACE-cme did not receive financial support for the production of this recording.

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.